alphaxalone
Pre-clinical- Indications
- Anesthesia, Sedation
Company intelligence / Profile preview
Drawbridge Pharmaceuticals Pty Ltd
Malvern, Victoria, Australiapitchbook.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Drawbridge Pharmaceuticals initiated a Phase 1C clinical trial of Phaxan (alphaxalone dissolved in sulfobutyl ether beta cyclodextrin) in 2013. The trial was a randomized double blind, dose-finding study using a Bayesian design to compare the anesthetic properties of Phaxan with propofol.
- Therapeutic areas
- OtherNeurology
- Modalities
- Small moleculesNeuroactive steroid compounds
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Drawbridge Pharmaceuticals Pty Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Drawbridge Pharmaceuticals Pty Ltd.